FMI Provides Therapeutic Nuclear Medicines Market Projections in its Revised Report, COVID-19 Pandemic Shaping Global De
A recent market study published by FMI u2013 u201cTherapeutic Nuclear Medicines Market: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2028u201d consists of a comprehensive assessment of the most important market dynamics. On conducting a thorough research of the historic as well as current growth parameters of the therapeutic nuclear medicines market, the growth prospects are obtained with maximum precision. The therapeutic nuclear medicines market report features the unique and salient factors that are likely to significantly impact the development of the therapeutic nuclear medicines market during the forecast period. It can help market players to modify their manufacturing and marketing strategies to envisage maximum growth in the therapeutic nuclear medicines market in the upcoming years. The report provides detailed information about the current and future growth prospects of the therapeutic nuclear medicines market in the most comprehensive manner for the better understanding of readers. Chapter 1 u2013 Executive Summary The therapeutic nuclear medicines market report commences with an executive summary of the key findings and key statistics of the therapeutic nuclear medicines market. It also includes the market value (US$ million) estimates of the leading segments of the therapeutic nuclear medicines market. Chapter 2 u2013 Market Introduction Readers can find detailed taxonomy and the definition of the therapeutic nuclear medicines market in this chapter, which helps understand the basic information about the therapeutic nuclear medicines. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the therapeutic nuclear medicines market report. Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2930 Chapter 3 u2013 Global Economic Outlook This section highlights the healthcare spending of the top countries in each region. This section also explains the global and regional healthcare market outlook. The regional healthcare market focuses is analysed in depth to assess the political, economic and business environment outlook of the respective region. Chapter 4 u2013 Market Opportunity Analysis This chapter explains the key macro-economic factors that are expected to influence the growth of the therapeutic nuclear medicines market over the forecast period. Along with macroeconomic factors, this section also highlights the opportunity analysis for the therapeutic nuclear medicines market. It helps readers understand the market opportunity, based on which they can plan their strategies. Chapter 5 u2013 Market Dynamics This chapter highlights the key dynamics of the therapeutic nuclear medicines market, which include the drivers, restraints and trends. The supply-side drivers as well as the demand-side drivers of the therapeutic nuclear medicines market are explained well in this chapter. This chapter is expected to enable readers to understand the factors that are propelling the therapeutic nuclear medicines market, as well as those that are likely to hamper the growth of the therapeutic nuclear medicines market. Moreover, readers will understand the key trends followed by the leading manufacturers in the therapeutic nuclear medicines market. Chapter 6 u2013 Key Inclusions This chapter highlights the key inclusions of the therapeutic nuclear medicines market report, which include key regulations, reimbursement scenario and pipeline assessment. The analysis of the parent market helps readers understand the share of the global therapeutic nuclear medicines market in the overall radiopharmaceutical market. The key regulations section of this chapter highlights the FDA and EMA regulatory processes for the approval of drugs. The reimbursement scenario provides the CPT codes used for therapeutic nuclear medicines, as well as the detailed explanation about each CPT code. The pipeline assessment includes the list of clinical trials pertaining to therapeutic nuclear medicines around the globe. Chapter 7 u2013 North America Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 This chapter includes a detailed analysis of the growth of the North America therapeutic nuclear medicines market along with a country-wise assessment, which includes the U.S. and Canada. Readers can also find the key takeaways of this region, and market growth based on treatment type, disease type, end user and country of therapeutic nuclear medicines in the North America region. Chapter 8 u2013 Latin America Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 This chapter contains a snapshot of the Latin America therapeutic nuclear medicines market. It includes the growth prospects of the therapeutic nuclear medicines market in the leading LATAM countries such as Brazil, Mexico, Argentina and the rest of the Latin America region. Chapter 9 u2013 Western Europe Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 The important growth prospects of the therapeutic nuclear medicines market based on its radionuclide type, indication and distribution channel in several European countries, such as the U.K., Germany, France, Italy Spain and the rest of Western Europe, is included in this chapter. Chapter 10 u2013 Eastern Europe Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 This chapter highlights the growth of the therapeutic nuclear medicines market in Eastern Europe by focusing on Russia and Poland. This section also helps readers understand the key factors that are responsible for the growth of the therapeutic nuclear medicines market in Eastern Europe. Chapter 11 u2013 APECJ Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 Australia & New Zealand, India and ASEAN are the leading countries in the APECJ region that are the prime subjects of assessment to obtain the growth prospects of the APECJ therapeutic nuclear medicines market in this chapter. Readers can find detailed information about the growth parameters of the APEJ therapeutic nuclear medicines market during the period 2018-2028. Chapter 12 u2013 China Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 The key factors responsible for the robust growth of the China therapeutic nuclear medicines market is explained in this section. The market analysis by radionuclide type, indication and distribution channel of the therapeutic nuclear medicines market is explained in this section, which provides readers an in-depth analysis of the China therapeutic nuclear medicines market. Chapter 13 u2013 Japan Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 Readers can find important factors that can significantly impact the growth of the therapeutic nuclear medicines market in Japan during the forecast period based on the market segmentation. Chapter 14 u2013 MEA Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 This chapter provides information about the growth of the therapeutic nuclear medicines market in the major countries of the MEA region, such as GCC Countries and South Africa, during the period 2018-2028. Chapter 15 u2013 Forecast Factors u2013 Relevance and Impact This chapter highlights the key factors taken into consideration which forecasting the market value of the global therapeutic nuclear medicines market. The impact of this forecast factor in different regions is also mentioned in this chapter. Chapter 16 u2013 Market Structure Analysis This section explains the tier structure of the global therapeutic nuclear medicines market, which helps readers understand the percent share of the market based on the tier 1, tier 2 and tier 3 players in the therapeutic nuclear medicines market. This section also explains the company share analysis for the therapeutic nuclear medicines market, which helps readers understand the market share held by the key players of the therapeutic nuclear medicines market. Chapter 17 u2013 Competition Landscape In this chapter, readers can find a comprehensive list of all the leading manufacturers in the therapeutic nuclear medicines market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, recent company developments and SWOT analysis. Some of the players featured in the therapeutic nuclear medicines market report are Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, Inc., ANSTO, Lantheus Medical Imaging, Inc., Eckert & Ziegler and International Isotopes Inc. Chapter 18 u2013 Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Region This chapter explains how the therapeutic nuclear medicines market will grow across various geographic regions such as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan (APECJ), China, Japan and the Middle East & Africa (MEA). Chapter 19 u2013 Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Radionuclide Type Based on the treatment type, the therapeutic nuclear medicines market is segmented into Radium-223, Iodine-131, Leutitium-177, Yttrium-90, Samarium-153, Strontium-89, Rhenium-188 Rhenium-186, Erbium-169, Phosphorus-32 and others. In this chapter, readers can find a detailed analysis of the therapeutic nuclear medicines market by different radionuclide types and their expected growth over the forecast period. Chapter 20 u2013 Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Indication Based on the indication, the therapeutic nuclear medicines market is segmented as prostate cancer, painful bone metastases, thyroid cancer, neuroblastoma, synovitis, non-Hodgkins lymphoma, hepatic metastases, brain tumour and others. This section helps readers understand the penetration of different indications in the therapeutic nuclear medicines market over the forecast period. To Buy This Research Report @ https://www.futuremarketinsights.com/checkout/2930 Chapter 21 u2013 Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Distribution Channel Based on the distribution channel, the therapeutic nuclear medicines market is segmented into hospitals, ambulatory surgical centres and cancer research institutes. In this chapter, readers can understand the market attractive analysis based on the distribution channel. Chapter 22 u2013 Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment, 2018-2028 This section explain the global market analysis and forecast for the therapeutic nuclear medicines market. It also highlights the incremental opportunity for the therapeutic nuclear medicines market along with the absolute dollar opportunity for every year between the forecast period of 2018-2028. Chapter 23 u2013 Assumptions and Acronyms This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report. Chapter 24 u2013 Research Methodology This chapter helps readers understand the research methodology followed to obtain various conclusions and important qualitative information & quantitative information about the therapeutic nuclear medicines market. ABOUT US: Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMIu2019s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers. CONTACT US: Mr. Abhishek Budholiya Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: sales@futuremarketinsights.com For Media Enquiries: press@futuremarketinsights.com
133 views • 12 slides